| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| Activin A | HOTDMF GMP-ACAH37 | GMP Human Activin A / INHBA Protein | Human | CHO | ![]() | SDS-PAGE | $605.00 50ug | ||
| Activin A | GMP Human Activin A / INHBA Protein | Human | CHO | ![]() | SDS-PAGE | $5090.00 500ug | |||
| Activin A | Human Activin A / INHBA Protein, Tag Free | Human | HEK293 | ![]() | SDS-PAGE | $300.00 25ug | |||
| Activin A | Human Latent Activin A / INHBA Protein, His Tag | Human | HEK293 | ![]() | SDS-PAGE | $485.00 100ug | |||
| Activin A | Human Activin A / INHBA Protein (E. coli), premium grade | Human | E. coli | ![]() | SDS-PAGE | $275.00 20ug | |||
| Activin A | Human Activin A / INHBA Superior Active Mutant Protein, premium grade | Human | E. coli | HPLCSDS-PAGE | $330.00 20ug | ||||
| Activin A | Human Activin A / INHBA Protein, premium grade | Human | CHO | ![]() | SDS-PAGE | $275.00 20ug | |||
| Activin A | Human Activin A / INHBA Protein, Research Grade | Human | CHO | ![]() | SDS-PAGE | $180.00 20ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| BLU-782 | BLU-782; IPN-60130 | Phase 2 Clinical | Blueprint Medicines Corp, Ipsen SA | Myositis Ossificans | Details |
| Zilurgisertib | INCB-000928; INCB-00928 | Phase 2 Clinical | Incyte Corp | Polycythemia Vera; Renal Insufficiency; Anemia; Myelodysplastic Syndromes; Ossification, Heterotopic; Multiple Myeloma; Primary Myelofibrosis; Myositis Ossificans; Thrombocythemia, Essential | Details |
| KER-047 | KER-047; TRND482477 | Phase 1 Clinical | National Center For Advancing Translational Sciences | Anemia, Iron-Deficiency; Myositis Ossificans | Details |
| Itacnosertib | TP-0184 | Phase 1 Clinical | Tolero Pharmaceuticals Inc, Sumitomo Dainippon | Solid tumours; Anemia | Details |
| BCX-9250 | BCX-9250 | Phase 1 Clinical | Biocryst Pharmaceuticals Inc | Myositis Ossificans | Details |
| HS135 | HS-135 | Phase 1 Clinical | 35Pharma Inc | Hypertension, Pulmonary; Heart Failure, Diastolic; Pulmonary Arterial Hypertension | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Momelotinib Dihydrochloride | CYT-387; GS-0387; GSK-3070785 | Approved | Gilead Sciences Inc, Cytopia Pty Ltd | Ojjaara, Omjjara | United States | Primary Myelofibrosis; Anemia | Glaxosmithkline Llc, Glaxosmithkline Plc | 2023-09-15 | Polycythemia Vera; Anemia; Myelodysplastic Syndromes; Neoplasms; Myeloproliferative Disorders; Pancreatic Intraductal Neoplasms; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Splenomegaly; Thrombocythemia, Essential; Carcinoma, Non-Small-Cell Lung | Details |